GlassScriptPhysician profile
Alexander W Ramsay
NPI 1871592089
$10,453.20
in general payments reported to CMS, 2019-2025
54 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,540 · 2020: $417 · 2021: $462 · 2022: $776 · 2023: $1,431 · 2024: $4,216 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,059 · Consulting Fee: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,058.65 |
| Consulting Fee | $2,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $3,079.12 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Dendreon Pharmaceuticals LLC | $1,489.06 | 2019-2025 | Provenge |
| Boston Scientific Corporation | $461.12 | 2019-2025 | General - Erectile Dysfunction, Ams 700, Rezum Generator |
| Coloplast Corp | $449.26 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $362.62 | 2023-2025 | Gemtesa, Orgovyx |
| Neotract INC. | $295.38 | 2019 | |
| Olympus America INC. | $283.94 | 2023-2025 | Itind System |
| Teleflex LLC | $242.71 | 2022-2023 | Urolift |
| Merck Sharp & Dohme LLC | $241.43 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Axonics, INC. | $237.11 | 2020-2024 | Axonics |
| Antares Pharma, INC. | $236.32 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Endo Pharmaceuticals INC. | $228.04 | 2019-2023 | Xiaflex |
| Janssen Biotech, INC. | $219.69 | 2019-2025 | Rybrevant, Carvykti |
| Ferring Pharmaceuticals INC. | $210.74 | 2019-2025 | Adstiladrin |
| Angiodynamics, INC. | $210.41 | 2023 | Nanoknife |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Ramsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.